Innovation, Affordability, Access: Alzheimer Disease Drugs and the Inflation Reduction Act
The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
Physicians' Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most?
Do the Incentives in 3-Tier Pharmaceutical Benefit Plans Operate as Intended? Results From a Physician Leadership Survey
